Risk factor
Negligible price volatility
Profitability factor
Good growth
In Guru Portfolios
About
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, un
Target Price
The average target price of RPRX is 63.5 and suggests 4.23% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio